Motility
Signal score, how each part rates
ActionabilityPrevalenceStakesEvidence strengthNovelty
See the full rubric →Avoidant/restrictive food intake across the gastrointestinal tract.
Clinical takeawayScreen for ARFID in patients with non-esophageal GI disorders (IBS, FD, constipation) using NIAS subscales (picky eating ≥10, appetite ≥9, fear ≥10) and DSM-5 impairment criteria, particularly in those with depressive symptoms or food-related abdominal pain.
What it foundARFID+ prevalence was higher in non-esophageal disorders (24%) vs. esophageal disorders (11%) (OR=2.7, p<0.001), with fear-based food avoidance contributing to pain-related restrictive eating (β=0.3, p<0.001). ARFID+ was defined as NIAS+ (picky eating ≥10, appetite ≥9, fear ≥10) plus DSM-5 impairment.
ContextConfirms ARFID as a significant comorbidity in non-esophageal GI disorders, extending prior evidence of its association with functional GI conditions.
Emergingsuggested applicable standard· American College of Gastroenterology, 'ACG and CAG Clinical Guideline: Management of Dyspepsia', 2017
American College of Gastroenterology, 'ACG and CAG Clinical Guideline: Management of Dyspepsia', 2017 · reviewed 2026-07-21 ↗After excluding organic causes and confirming H. pylori test-of-cure, manage functional dyspepsia by eradicating H. pylori if positive and giving a PPI (4-8 weeks, dosed 30-60 min before meals); for persistent symptoms consider neuromodulators (e.g., low-dose TCAs like amitriptyline 10-50 mg QHS) for refractory cases, particularly in EPS, or prokinetics cautiously in selected PDS cases. Initial evaluation follows ACG/CAG 2017: test-and-treat H. pylori in patients under 60 without alarm features, and EGD for age ≥60, alarm features, or high gastric-cancer-risk groups. Add psychological therapies (CBT, gut-directed hypnotherapy) and lifestyle measures.
Routhiaux K … Tack J · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗